CD274 and non-small cell lung carcinoma: In this regard, Ayers et al. [23] used the Nanostring nCounter platform, which is compatible with formalin-fixed paraffin-embedded (FFPE) specimens in the clinical setting, to find evidence that the genomic signature of 18 genes is a reliable tool for identifying pro-inflammatory T-cell phenotypes in NSCLC patients who are likely to respond to PD-L1 inhibition therapy.